Vitreous concentration of topically applied brimonidine-purite 0.15%

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 4, 2006, Pages 242-246

  Kent, Alexander R ^a,c   King, Lowery ^b   Bartholomew, Luanna R ^c  

^a Eyecare Physicians and Surgeons   (United States)

^b Retina Consultants of Charleston   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BRIMONIDINE; BRIMONIDINE PURITE; EYE DROPS; UNCLASSIFIED DRUG; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; QUINOXALINE DERIVATIVE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; FEMALE; HUMAN; INFUSION SYSTEM; MALE; NEUROPROTECTION; VITRECTOMY; VITREOUS BODY; BIOAVAILABILITY; MASS FRAGMENTOGRAPHY; METABOLISM; TISSUE DISTRIBUTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; OPHTHALMIC SOLUTIONS; QUINOXALINES; TISSUE DISTRIBUTION; VITRECTOMY; VITREOUS BODY;

EID: 33749119135     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.242     Document Type: Article

References (11)

1. Katz, LJ. Twelve-month evaluation of brimonidine-Purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma 11:119-126, 2002.
2. Wheeler, L.A., Woldemussie, E., and Lai, R. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur. J. Ophthalmol. 11:S30-S35, 2001.
3. Wheeler, L.A., Woldemussie, E., and Lai, R. Role of alpha-2 agonists in neuroprotection. Surv. Ophthalmol. 48:547-551, 2003.
4. Gao, H., Qiao, X., Cantor, L.B., et al. Upregulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 120:797-803, 2002.
5. Aviles-Trigueros, M., Mayor-Torroglosa, S., Garcia-Aviles, A., et al. Transient ischemis of the retina results in massive degeneration of the retinotectal projection: Long-term neuroprotection with brimonidine. Exp. Neurol. 184:767-777, 2003.
6. Acheampong, A.A., Shackleton, M., John, B., et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30:421-429, 2002.
7. Kent, A.R., Nussdorf, J.D., David, R., et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 108:784-787, 2001.
8. Yoles, E., Wheeler, L.A., and Schwartz, M. Alpha-2 adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 40:65-73,1999
9. [erratum in Invest. Ophthalmol. Vis. Sci. 40:2470, 1999].
10. Wheeler, L.A., Lai, R., and Woldemussie, E. From the lab to the clinic: Activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur. J. Ophthalmol. 9(Suppl 1):S17-S21, 1999.
11. Krupin, T., Lichmann, JM., Greenfield, D.S., et al. Low-Pressure Glaucoma Study Group. The low-pressure glaucoma treatment (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 112:376-385, 2005.